458 Studies Now Enrolling
A Phase Ib/II study of pembrolizumab, ibrutinib and rituximab in recurrent central nervous system lymphoma (CNSL)
Study of Pembrolizumab, Ibrutinib and Rituximab in Patients with Primary Central Nervous System Lymphoma (PCNSL)
| Sponsor: | NA |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAT7683 |
| U.S. Govt. ID: | NCT04421560 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
In this research study, we are looking to see how safe and effective the combination of pembrolizumab, ibrutinib and rituximab is in your type of cancer. The FDA (the U.S. Food and Drug Administration) has not approved pembrolizumab, ibrutinib or rituximab for your specific disease but these have been approved for other uses including other types of non-Hodgkins lymphoma.
